ArticleFrontiers in endocrinology2025
Effect of metabolic syndrome on coronary artery atherosclerotic plaque in type 2 diabetes mellitus patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effect of MS on coronary artery plaques detected by coronary computed tomography angiography (CCTA) in type 2 diabetes mellitus (T2DM) patients is not fully understood. This study aimed to investigate the effect of MS and its components on coronary artery plaques by comparing CCTA characteristics, including plaque types, the severity of coronary plaques and high-risk plaques between T2DM patients with and without MS. Methods: This study retrospectively enrolled 2,431 patients with T2DM who underwent Coronary Computed Tomography Angiography (CCTA) at West China Hospital between January 2015 to February 2022. These patients were divided into two groups based on the presence or absence of metabolic syndrome (MS). The plaque type, coronary artery stenosis, extent of coronary artery plaques, high-risk coronary plaque features, the segment involvement score (SIS), the segment stenosis score (SSS) and multivessel disease (MVD) based on CCTA data were evaluated and compared between two groups. Results: For T2DM patients, those with MS (61.5%, n=1496) had more noncalcified/mixed plaques, more nonobstructive stenosis and higher SIS and SSS values than those without (P < 0.05 for all). The proportion of patients with any noncalcified plaque, any mixed plaque, SIS≥4 and SSS≥7were in parallel with the numbers of MS components (P for trend<0.01 for all). Multivariate logistic regression revealed that MS were independently associated with any noncalcified plaque (OR=1.232, P =0.024), any mixed plaque (OR=1.307, P=0.006), any nonobstructive stenosis(OR=1.615, P = 0.001), SIS≥4 (OR=1.529; P<0.001), SSS≥7 (OR=1.387; P=0.001), and any spotty calcification (OR=1.870, P =0.001) in T2DM patients after adjusting for the confounding factors. Conclusion: MS is independently associated with adverse coronary artery plaque characteristics in Type 2 Diabetes Mellitus (T2DM) patients, including increased mixed, noncalcified, nonobstructive, spotty calcification plaques, as well as extensive coronary artery disease (CAD). These findings highlight the need for early detection and management of MS to reduce cardiovascular risks in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.